In:
International Journal of Cancer, Wiley, Vol. 150, No. 2 ( 2022-01-15), p. 317-326
Abstract:
What's new? Reasons for discontinuing treatment with the anti‐PD‐1 antibodies nivolumab and pembrolizumab can vary significantly among melanoma patients. Moreover, the optimal treatment duration for these drugs remains unclear. In this observational study on anti‐PD‐1 discontinuation, most patients with advanced melanoma who had complete or partial response at anti‐PD‐1 discontinuation experienced ongoing response, with potential survival benefits. Shorter time to first response of anti‐PD‐1 monotherapy and partial response at discontinuation were associated with later progression of disease. Elective discontinuation, by contrast, was linked to a reduced likelihood of subsequent progression. Anti‐PD‐1 retreatment exhibited clinical activity against melanoma, warranting further investigation.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8